Please login to the form below
SEC
This page shows the latest SEC news and features for those working in and with pharma, biotech and healthcare.
bluebird bio provides update on 2seventy bio spin-off
bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC).
Latest news
-
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
NextCure did not reveal why Lilly decided to terminate the agreement, saying in a brief US Securities and Exchange Commission (SEC) filing:. ... Shares in the biotech fell shortly after the SEC filing was released – the company is also due to present
-
MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
In an SEC filing, it said the cuts are focused on 'further optimising the company’s manufacturing and supply network, as well as reducing its global real estate footprint'.
-
France’s Innate Pharma eyes $100m Nasdaq IPO
filed with the US Securities &Exchange Commission (SEC).
-
‘Missing protein’ biotech Stoke raises $142m in IPO
In Stoke’s IPO prospectus filed with the Securities &Exchange Commission (SEC), the company says it will file for approval to start trials of STK-001 early in 2020 and will
-
‘Missing protein’ biotech Stoke raises $142m in IPO
In Stoke’s IPO prospectus filed with the Securities &Exchange Commission (SEC), the company says it will file for approval to start trials of STK-001 early in 2020 and will
More from news
Approximately 2 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Creating a successful global compliance programme
The importance of effective compliance programmes was highlighted in the DOJ and SEC’s Resource Guide to the US Foreign Corrupt Practices Act, which describes in detail the hallmarks of a
-
Deal Watch January 2018
investors. However, in the meantime the US Securities and Exchange Commission (SEC) has issued a lawsuit against some traders for insider trading based on a series of suspicious transactions that made
-
US health reforms
In March, the Securities and Exchange Commission (SEC) only narrowly blocked this move.
-
Deal Watch - May 2017
Two months later Abbott asked Alere to cancel the transaction because of a SEC inquiry into accounting issues at Alere and offered $30m to $50m compensation. ... Alere rejected the offer. Abbott had been aware of the SEC inquiry before the deal was signed
-
On the road with the millennial HCP
Yeah I'll put Andy on. Just hang on a sec, he's just sorting our next lift.”.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
RSA announces three new UK hires
In 2009, de Luis moved to the UK with SEC Recruitment and spent three years focussing on the Spanish pharmaceutical market across a number of functional areas.
-
Scottish cabinet reshuffle sees Alex Neil made health secretary
Commenting on Twitter, Sturgeon said: “It has been a privilege to have been Health Sec[retary] - my thanks to all the wonderful people I have worked with.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
SALES ACCELERANT
We help companies to engage prim/sec care healthcare professionals more efficiently and effectively to drive sales growth.
-
SEC Pharma
Analysis, SEC can assist wherever you are looking to hire or work throughout the UK and Europe.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
